Literature DB >> 26574188

External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Chen-Yan Zhao1, Zheng Jiao1, Jun-Jun Mao1,2, Xiao-Yan Qiu1.   

Abstract

AIM: Several tacrolimus population pharmacokinetic models in adult renal transplant recipients have been established to facilitate dose individualization. However, their applicability when extrapolated to other clinical centres is not clear. This study aimed to (1) evaluate model external predictability and (2) analyze potential influencing factors.
METHODS: Published models were screened from the literature and were evaluated using an external dataset with 52 patients (609 trough samples) collected by postoperative day 90 via methods that included (1) prediction-based prediction error (PE%), (2) simulation-based prediction- and variability-corrected visual predictive check (pvcVPC) and normalized prediction distribution error (NPDE) tests and (3) Bayesian forecasting to assess the influence of prior observations on model predictability. The factors influencing model predictability, particularly the impact of structural models, were evaluated.
RESULTS: Sixteen published models were evaluated. In prediction-based diagnostics, the PE% within ±30% was less than 50% in all models, indicating unsatisfactory predictability. In simulation-based diagnostics, both the pvcVPC and the NPDE indicated model misspecification. Bayesian forecasting improved model predictability significantly with prior 2-3 observations. The various factors influencing model extrapolation included bioassays, the covariates involved (CYP3A5*3 polymorphism, postoperative time and haematocrit) and whether non-linear kinetics were used.
CONCLUSIONS: The published models were unsatisfactory in prediction- and simulation-based diagnostics, thus inappropriate for direct extrapolation correspondingly. However Bayesian forecasting could improve the predictability considerably with priors. The incorporation of non-linear pharmacokinetics in modelling might be a promising approach to improving model predictability.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  adult renal transplant recipients; external evaluation; non-linear kinetics; population pharmacokinetics; tacrolimus

Mesh:

Substances:

Year:  2016        PMID: 26574188      PMCID: PMC4834594          DOI: 10.1111/bcp.12830

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  69 in total

1.  Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients.

Authors:  C J Hesse; C C Baan; A H M M Balk; H J Metselaar; W Weimar; T van Gelder
Journal:  Transplant Proc       Date:  2002-11       Impact factor: 1.066

2.  Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies.

Authors:  Yann Merlé; Azzedine Aouimer; Michel Tod
Journal:  J Biopharm Stat       Date:  2004-02       Impact factor: 1.051

Review 3.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

5.  Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg.

Authors:  I Bekersky; D Dressler; Q A Mekki
Journal:  Clin Ther       Date:  1999-12       Impact factor: 3.393

6.  Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose.

Authors:  I Bekersky; D Dressler; Q Mekki
Journal:  J Clin Pharmacol       Date:  2001-03       Impact factor: 3.126

7.  Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy.

Authors:  Tsutomu Shimada; Ai Terada; Koichi Yokogawa; Hiroko Kaneko; Masaaki Nomura; Kyosuke Kaji; Shuichi Kaneko; Ken-Ichi Kobayashi; Ken-Ichi Miyamoto
Journal:  Transplantation       Date:  2002-11-27       Impact factor: 4.939

8.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.

Authors:  Christine E Staatz; Charlene Willis; Paul J Taylor; Susan E Tett
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

9.  [Cyclosporin pharmacokinetic modeling in renal transplant patients].

Authors:  B Porta Oltra; J J Pérez Ruixo; N V Jiménez Torres; L Pallardó Mateu
Journal:  Farm Hosp       Date:  2004 Jan-Feb

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more
  22 in total

1.  Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.

Authors:  Yu-Si Chen; Zi-Qi Liu; Rong Chen; Lei Wang; Ling Huang; Xiao Zhu; Tian-Yan Zhou; Wei Lu; Ping Ma
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

2.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.

Authors:  Yan Gong; Ming Yang; Yongfeng Sun; Jing Li; Yongning Lu; Xingang Li
Journal:  Eur J Hosp Pharm       Date:  2019-01-19

4.  Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis.

Authors:  Lizhi Chen; Yunyun Yang; Xuebin Wang; Chenyu Wang; Weiwei Lin; Zheng Jiao; Zhuo Wang
Journal:  Pharmgenomics Pers Med       Date:  2021-09-03

5.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

6.  Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.

Authors:  Tom M Nanga; Thao T P Doan; Pierre Marquet; Flora T Musuamba
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

7.  External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.

Authors:  Jun-Jun Mao; Zheng Jiao; Hwi-Yeol Yun; Chen-Yan Zhao; Han-Chao Chen; Xiao-Yan Qiu; Ming-Kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

8.  Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.

Authors:  Can Hu; Wen-Jun Yin; Dai-Yang Li; Jun-Jie Ding; Ling-Yun Zhou; Jiang-Lin Wang; Rong-Rong Ma; Kun Liu; Ge Zhou; Xiao-Cong Zuo
Journal:  Eur J Clin Pharmacol       Date:  2018-07-17       Impact factor: 2.953

9.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.

Authors:  Celeste Bloomfield; Christine E Staatz; Sean Unwin; Stefanie Hennig
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.

Authors:  Huan-Xi Zhang; Chang-Cheng Sheng; Long-Shan Liu; Bi Luo; Qian Fu; Qun Zhao; Jun Li; Yan-Feng Liu; Rong-Hai Deng; Zheng Jiao; Chang-Xi Wang
Journal:  Br J Clin Pharmacol       Date:  2019-02-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.